Innate Pharma (IPHYF) Stock Price, News & Analysis

Company Overview

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Key Stats

• Today's Range: $1.45 to $1.45
• 50-Day Range: $1.45 to $2.90
• 52-Week Range: $1.45 to $1.76
• Volume: N/A
• Average Volume: 1,445 shs
• Market Capitalization: $121.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Innate Pharma Stock Analysis - MarketRank™

Innate Pharma scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Innate Pharma.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Innate Pharma has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.04% of the float of Innate Pharma has been sold short.

Short Interest Ratio / Days to Cover

Innate Pharma has a short interest ratio ("days to cover") of 210, which indicates bearish sentiment.

Change versus previous month

Short interest in Innate Pharma has recently increased by 6,900.00%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Innate Pharma does not currently pay a dividend.

Dividend Growth

Innate Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.04% of the float of Innate Pharma has been sold short.

Short Interest Ratio / Days to Cover

Innate Pharma has a short interest ratio ("days to cover") of 210, which indicates bearish sentiment.

Change versus previous month

Short interest in Innate Pharma has recently increased by 6,900.00%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.32

News Sentiment

Innate Pharma has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Innate Pharma this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Innate Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.89% of the stock of Innate Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

IPHYF Stock Analysis - Frequently Asked Questions

How have IPHYF shares performed this year?

Innate Pharma's stock was trading at $2.90 at the beginning of 2025. Since then, IPHYF shares have decreased by 50.0% and is now trading at $1.45.
View the best growth stocks for 2025 here.

How do I buy shares of Innate Pharma?

Shares of IPHYF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 5/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:IPHYF
• Previous Symbol: NASDAQ:IPHYF
• CIK: 1598599
• Web: www.innate-pharma.com
• Phone: (343) 030-3030
• Fax: 33-04-30-30-30-00
• Employees: 179
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $66.71 million
• Price / Sales: 1.82
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.70 per share
• Price / Book: 2.07

Miscellaneous

• Outstanding Shares: 83,830,000
• Free Float: 57,097,000
• Market Cap: $121.55 million
• Optionable: Not Optionable
• Beta: 0.55